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ABSTRACT In recent years, several newly discovered tick-borne viruses causing a
wide spectrum of diseases in humans have been ascribed to the Phlebovirus genus
of the Bunyaviridae family. The nonstructural protein (NSs) of bunyaviruses is the
main virulence factor and interferon (IFN) antagonist. We studied the molecular
mechanisms of IFN antagonism employed by the NSs proteins of human apatho-
genic Uukuniemi virus (UUKV) and those of Heartland virus (HRTV) and severe fever
with thrombocytopenia syndrome virus (SFTSV), both of which cause severe disease.
Using reporter assays, we found that UUKV NSs weakly inhibited the activation of
the beta interferon (IFN-) promoter and response elements. UUKV NSs weakly an-
tagonized human IFN- promoter activation through a novel interaction with mito-
chondrial antiviral-signaling protein (MAVS), conﬁrmed by coimmunoprecipitation
and confocal microscopy studies. HRTV NSs efﬁciently antagonized both IFN- pro-
moter activation and type I IFN signaling pathways through interactions with TBK1,
preventing its phosphorylation. HRTV NSs exhibited diffused cytoplasmic localization.
This is in comparison to the inclusion bodies formed by SFTSV NSs. HRTV NSs also
efﬁciently interacted with STAT2 and impaired IFN--induced phosphorylation but
did not affect STAT1 or its translocation to the nucleus. Our results suggest that a
weak interaction between STAT1 and HRTV or SFTSV NSs may explain their inability
to block type II IFN signaling efﬁciently, thus enabling the activation of proinﬂamma-
tory responses that lead to severe disease. Our ﬁndings offer insights into how
pathogenicity may be linked to the capacity of NSs proteins to block the innate im-
mune system and illustrate the plethora of viral immune evasion strategies utilized
by emerging phleboviruses.
IMPORTANCE Since 2011, there has been a large expansion in the number of
emerging tick-borne viruses that have been assigned to the Phlebovirus genus.
Heartland virus (HRTV) and SFTS virus (SFTSV) were found to cause severe disease in
humans, unlike other documented tick-borne phleboviruses such as Uukuniemi virus
(UUKV). Phleboviruses encode nonstructural proteins (NSs) that enable them to
counteract the human innate antiviral defenses. We assessed how these proteins in-
teracted with the innate immune system. We found that UUKV NSs engaged with in-
nate immune factors only weakly, at one early step. However, the viruses that cause
more severe disease efﬁciently disabled the antiviral response by targeting multiple
components at several stages across the innate immune induction and signaling
pathways. Our results suggest a correlation between the efﬁciency of the virus pro-
tein/host interaction and severity of disease.
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Phleboviruses are enveloped, single-stranded RNA viruses belonging to the Bunya-viridae family. The genus is comprised of over 70 viruses, broadly divided into the
sandﬂy fever group and the Uukuniemi-like group, according to their genomic, anti-
genic, and vector similarities (1, 2). The viral genome is composed of the large (L),
medium (M), and small (S) RNA segments. The L segment encodes the viral RNA-
dependent RNA polymerase, the M segment encodes the precursor for the viral
glycoproteins (Gn and Gc), and the S segment encodes the nucleocapsid (N) protein
and a nonstructural protein (NSs). Viruses belonging to the sandﬂy fever group are
transmitted by dipterans (phlebotomines and mosquitoes) and encode a nonstructural
protein (NSm) at the N terminus of their glycoprotein precursor, whereas those within
the Uukuniemi-like group are transmitted by ticks and do not encode an NSm protein
within their genome (3, 4).
Tick-borne (TiBo) phleboviruses were not considered a public health threat until the
emergence of a novel tick-borne Phlebovirus, named severe fever with thrombocyto-
penia syndrome virus (SFTSV), in China in 2009. The virus caused disease in humans,
with a case fatality rate of 12% to 30%, and patients presented with fever, thrombo-
cytopenia, hemorrhagic manifestations, and multiorgan failure (5, 6). SFTSV was later
identiﬁed in patients exhibiting similar symptoms in Japan and South Korea (7, 8).
Shortly after the emergence of SFTSV, a closely related virus, Heartland virus (HRTV),
was isolated from patients in Missouri and Tennessee in the United States who
presented with fever, fatigue, thrombocytopenia, leukopenia, and, in some cases,
multiorgan failure and hemorrhage (9–11). Unlike highly pathogenic TiBo phlebovi-
ruses, some viruses, such as the prototype Uukuniemi virus (UUKV), are apathogenic.
While antibodies against UUKV-like viruses have been detected in birds, rodents, cows,
and humans (12, 13), no disease of medical or veterinary signiﬁcance has been
associated with UUKV infection (14). In recent years, many novel and emerging viruses
have been assigned to the Phlebovirus UUKV-like group, including Lone Star virus (LSV)
(15), Hunter Island group virus (HIGV) (16), Malsoor virus (MALV) (17), Antigone virus
(ANTV) (18), blacklegged tick Phlebovirus (BTPV), and American dog tick Phlebovirus
(ADTPV) (19). The continuing expansion of the host and geographical ranges of
tick-borne phleboviruses poses a potential risk to both human and animal health.
Following infection of a susceptible host, viruses confront the innate immune
system, the ﬁrst line of defense against viral infections. RNA viruses produce products
such as double-stranded RNA (dsRNA) and 5=-triphosphorylated uncapped single-
stranded RNAs (ssRNAs) during replication of their viral genome. These products, or
pathogen-associated molecular patterns (PAMPs), are detected by host cell RNA heli-
cases such as those encoded by melanoma differentiation-associated gene 5 (MDA-5)
and retinoic acid-inducible gene I (RIG-I), respectively (20). As some negative-strand
RNA viruses produce little or undetectable amounts of dsRNA during replication (21,
22), it is hypothesized that these viruses are sensed mainly by RIG-I, through the
generation of single-stranded RNA (ssRNA) with uncapped 5= triphosphate ends (23,
24). Binding of viral RNA to RIG-I results in its activation and the initiation of down-
stream signaling pathways. Activated RIG-I can recruit the adaptor mitochondrial
antiviral signaling protein (MAVS, also known as IPS-1, Cardif, or VISA) through caspase
activation and recruitment domains (CARD), which leads to the subsequent activation
of interferon (IFN) regulatory factor-3 (IRF-3), IRF-7, and NF-B via kinases TBK1/IB
kinase- (TBK1/IKK) and IKK/IKK, respectively. Activated IRF-3 and NF-B can then
translocate to the nucleus and act as transcription factors for the initiation of beta
interferon (IFN-) mRNA synthesis (25, 26). Following IFN induction, secreted IFN
activates the IFN signaling pathway in neighboring cells by binding to IFN receptors,
triggering the activation of the JAK/STAT pathway. Type I IFN signaling results in the
formation of the heterotrimer ISGF3, composed of STAT1, STAT2, and IRF-9, which binds
to the interferon-stimulated response element (ISRE) and enhances transcription of
numerous antiviral interferon-stimulated genes (ISGs) (27).
Bunyaviruses have evolved countermeasures to evade the host innate immune
system. The NSs protein is a nonessential protein encoded by some members of the
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Bunyaviridae and has been shown to contribute to virus virulence and pathogenesis by
acting as an IFN antagonist (28, 29). Within the Phlebovirus genus, studies on the IFN
antagonist activity of NSs proteins have focused on mosquito-borne phleboviruses, in
particular, that encoded by Rift Valley fever virus (RVFV). With the emergence of highly
pathogenic SFTSV, research interests have focused on understanding its underlying
molecular mechanisms of pathogenicity. As a result, quickly after its emergence, SFTSV
NSs was characterized as a potent antagonist of IFN induction and signaling, through
the spatial isolation of TRIM25 and RIG-I (30), TBK1 (31, 32), IRF-3 (31, 32), and STAT1 and
STAT2 (33, 34) in NSs-containing, round, cytoplasmic inclusion bodies (IB) or viroplasms.
Although the interaction between SFTSV NSs and IKK or IRF-3 was reported to be
indirect, facilitated through the interaction between SFTSV NSs and TBK1 (32), one
study also showed a direct interaction of SFTSV NSs with IKK (31). Similarly, while one
study reported a direct interaction between SFTSV NSs and RIG-I (30), no direct
interaction was observed in another study (31). We have previously shown that UUKV
NSs also acts as an IFN antagonist (35). However, little is known about the mechanism
by which UUKV NSs and other tick-borne Phlebovirus NSs proteins impair the innate
immune system.
Here we report a study of UUKV and HRTV NSs proteins, focused on understanding
their role in antagonizing the human innate immune system at the molecular level, in
comparison to the well-characterized SFTSV NSs. We observed that UUKV NSs weakly
suppresses IFN induction but not IFN signaling, compared to the potent effects of HRTV
and SFTSV NSs in both pathways. Our ﬁndings indicate that the weak suppression of
IFN induction by UUKV NSs occurs through a direct interaction with MAVS, an early
effector protein in the RIG-I signaling pathway. The weak effects of UUKV NSs as an IFN
antagonist may provide an explanation for its inability to cause disease in humans,
which is in agreement with previous studies (35). For the ﬁrst time, we show that HRTV
NSs acts as a potent antagonist of IFN induction and type I IFN signaling. Moreover, we
observed that despite HRTV and SFTSV NSs proteins sharing only 63% amino acid
identity (5), some key characteristics of their IFN inhibitory activity are conserved. Our
data show that both proteins interact with TBK1 and antagonize its phosphorylation at
serine 172 to interfere with IFN induction and with STAT2 to block its phosphorylation
and thus interfere with type I IFN signaling. HRTV NSs showed diffused cytoplasmic
localization, unlike the inclusion bodies formed by SFTSV NSs to spatially isolate its
interacting partners in the IFN induction and signaling pathways. Additionally, we
demonstrate that type II IFN signaling is not inhibited by HRTV or SFTSV NSs proteins,
presumably due to a weak or indirect interaction of the NSs proteins with STAT1. The
inability of HRTV and SFTSV NSs proteins to efﬁciently block type II IFN signaling might
explain the activation of proinﬂammatory responses that lead to severe disease fol-
lowing virus infection.
The ﬁndings presented here expand our knowledge of phleboviral strategies to
modulate host innate immune responses and illustrate that TiBo Phlebovirus NSs
proteins can evolve divergent mechanisms to antagonize the IFN system.
RESULTS
Diversity of TiBo Phlebovirus NSs subcellular localization. The NSs protein of
bunyaviruses is known to exhibit very low conservation at the amino acid level in
comparison to other viral proteins (5, 36). Therefore, we speculated that the differences
in amino acid sequence could permit the NSs proteins to adopt different IFN
antagonism strategies. To begin a basic characterization of tick-borne Phlebovirus
NSs proteins, we ﬁrst compared the amino acid identities of UUKV (GenBank accession
no. AAA47959.1), HRTV (GenBank accession no. AFP33392.1), and SFTSV (GenBank
accession no. AJD86041.1) NSs proteins using CLUSTAL Omega (37, 38) (Table 1). While
UUKV NSs shares low amino acid sequence identity with HRTV (22.73%) and SFTSV
(22.22%) NSs, the identity between HRTV and SFTSV NSs proteins is 62.76% (Table 1).
Alignments of the amino acid sequences of NSs proteins relevant to this study are
shown in Fig. S1 in the supplemental material.
TiBo Phlebovirus Innate Immune Antagonism
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We next compared the subcellular localization of the NSs proteins of UUKV and
HRTV to that of SFTSV to give us insights into whether the mechanisms of IFN
antagonism between these proteins are divergent or conserved. Human A549 cells
were infected at a high multiplicity of infection (MOI) (3 focus-forming units [FFU]/cell)
and probed with the respective NSs antibodies 24 h postinfection (p.i.). In agreement
with previous reports (39), we observed cytoplasmic distribution of UUKV NSs with
small, punctate staining (Fig. 1A). Interestingly, despite the higher percentage of
identity between HRTV and SFTSV NSs, we noted that HRTV NSs showed diffused
cytoplasmic distribution, whereas SFTSV NSs formed characteristic inclusion bodies
(Fig. 1B and C). On the basis of these observations, our ﬁndings suggested that UUKV
NSs and HRTV NSs may utilize a mechanism different from that of the well-studied
SFTSV NSs to circumvent the IFN response.
UUKV, HRTV, and SFTSV NSs proteins, which were tagged at their C terminus with
a V5 tag, were used in the rest of this study to enable a comparison of the expression
levels of the tagged-NSs proteins in transient-expression assays. Thus, we additionally
compared the subcellular localization of the V5-tagged NSs proteins to that of native
NSs proteins following virus infection. Expression of V5-tagged UUKV, HRTV, or SFTSV
NSs in HEK293T cells revealed that their subcellular localization was like that described
for wild-type (wt) protein following virus infection in A549 cells (Fig. 1D).
Inhibition of IFN induction by TiBo Phlebovirus NSs proteins. We investigated
whether these NSs proteins could inhibit the IFN response at the level of IFN induction.
Brieﬂy, HEK293T cells were cotransfected with an inducer plasmid encoding the
N-terminal 2CARD domain of RIG-I (pCAGGS-FLAG-2CARD [a kind gift from B. Hale,
University of Zurich], here referred to as RIG-I N) and either untagged or V5-tagged
UUKV, HRTV, or SFTSV NSs. V5-tagged proteins were used to compare expression levels
of proteins in the assays. At 24 h posttransfection (p.t.), IFN production in these cells
was quantiﬁed using a biological IFN assay. A dose-dependent inhibitory effect of IFN
induction was observed for both wt and V5-tagged NSs proteins of all three viruses
(Fig. 2A). However, the inhibitory activity of UUKV NSs with respect to IFN induction was
distinctly weak compared to that seen with HRTV or SFTSV NSs. At the highest dose
(250 ng) of NSs-encoding plasmid, UUKV NSs expression resulted in approximately 60%
inhibition of IFN production, whereas that of HRTV and SFTSV NSs was 100% (Fig. 2A).
This observation agrees with our recent ﬁnding that UUKV NSs acts as a weak IFN
antagonist, shown by the creation of a recombinant UUKV lacking NSs (35). HRTV and
SFTSV NSs proteins strongly antagonized the production of IFN (Fig. 2A). A difference
in the levels of efﬁciency with which HRTV and SFTSV NSs can block IFN production was
observed. While an approximately 50% decrease in relative IFN production was ob-
served at the lowest dose of HRTV NSs (10 ng), this dose of SFTSV NSs resulted in an
almost 95% decrease in IFN production (Fig. 2A). However, examination of the cell
lysates by Western blotting revealed V5-tagged HRTV NSs expression levels that were
visibly lower than those seen with SFTSV and UUKV NSs proteins (Fig. 2B). In fact,
transfection of 50 ng of V5-tagged HRTV NSs resulted in expression levels similar to
those seen with 10 ng of V5-tagged SFTSV NSs (Fig. 2B), and the same level of inhibition
of IFN production was observed with these respective amounts (Fig. 2A). Regardless,
these results indicated that all NSs proteins examined were capable of inhibiting the
induction of IFN.
TABLE 1 Percentages of amino acid identity of tick-borne Phlebovirus proteins used in
this study
Virus
Amino acid identity (%)a
UUKV HRTV SFTSV
UUKV 100 22.73 22.22
HRTV 22.73 100 62.67
SFTSV 22.22 62.67 100
aValues are based on data from GenBank (accession numbers AAA47959.1, AFP33392.1, and AJD86041.1 for
UUKV, HRTV, and SFTSV NSs, respectively) and were generated using Clustal Omega.
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The transcription factor interferon regulatory factor 3 (IRF-3) is ubiquitously ex-
pressed in cells. Following activation of the IFN pathway, IRF-3 is phosphorylated by
TANK-binding kinase-1 (TBK1), which allows its homodimerization prior to translocation
to the nucleus (40–43). Thus, we investigated whether the NSs proteins inhibited the
induction of IFN by ultimately preventing the activation of IRF-3. HEK293T cells were
induced with a RIG-I N-encoding plasmid in the presence of 250 ng of untagged or
V5-tagged NSs proteins and were subsequently harvested for analysis of IRF-3 phos-
phorylation. IRF-3 phosphorylated at Ser386 could be readily detected in the mock cells
stimulated with RIG-I N and also in the presence of UUKV NSs (Fig. 2C). Almost
undetectable levels of phosphorylated IRF-3 were observed in the presence of HRTV
NSs or SFTSV NSs. Under all experimental conditions, the levels of total IRF-3 remained
unchanged. Similarly, when cell lysates were analyzed under nondenaturing conditions,
FIG 1 Subcellular localization of UUKV, HRTV, and SFTSV NSs. The subcellular localization of UUKV (A), HRTV (B),
or SFTSV (C) NSs proteins was analyzed by confocal microscopy. The indicated cell lines were infected with UUKV,
HRTV, and SFTSV at an MOI of 3 FFU/cell (or were mock infected), ﬁxed at 24 h p.i., permeabilized, and probed with
the appropriate NSs antibody. NSs proteins (green) and cell nuclei (blue) were visualized by confocal microscopy.
(D) The subcellular localization of V5-tagged NSs proteins was also investigated. HEK293T cells were transfected
with plasmids encoding UUKV, HRTV, or SFTSV NSs proteins tagged at their C terminus with a V5 tag. At 24 h
posttransfection, cells were ﬁxed, permeabilized, and probed with an anti-V5 antibody. DAPI-stained nuclei (blue)
and the V5-tagged NSs proteins (red) were visualized by confocal microscopy. Scale bars indicate 20 m.
TiBo Phlebovirus Innate Immune Antagonism
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the dimeric form of IRF-3 could be detected only in the presence of UUKV NSs but not
HRTV or SFTSV NSs. A shift in molecular weight was observed for the V5-tagged UUKV
NSs under nonreducing conditions (Fig. 2D).
Taken together, these data indicate that, in contrast to UUKV NSs, HRTV and SFTSV
NSs proteins can efﬁciently antagonize IFN induction, ultimately hindering the activa-
tion of IRF-3 and thus blocking activation of the IFN- promoter. On the other hand,
UUKV NSs, a weak IFN antagonist, is unable to completely inhibit the activation of IRF-3
and the subsequent production of IFN.
UUKV NSs exerts its IFN-antagonistic activity at the level of MAVS, while HRTV
NSs antagonizes at the level of TBK1. To elucidate the stage of the IFN induction
pathway at which UUKV and HRTV NSs proteins antagonize this response, we per-
formed an IFN- reporter assay in the presence of UUKV or HRTV NSs, using SFTSV NSs
as a control. Various effectors of the IFN induction pathway (constitutively active RIG-I
FIG 2 UUKV, HRTV, and SFTSV NSs proteins inhibit IFN induction. (A) The inhibitory effect of UUKV, HRTV, and SFTSV NSs proteins on IFN induction was
investigated by measuring the RIG-I N-induced induction of IFN production in HEK293T cells in the presence of increasing amounts of untagged or V5-tagged
NSs proteins. Cell culture supernatant was harvested 24 h posttransfection, and relative IFN units were quantiﬁed by a biological IFN assay in A549/BVDV-Npro
cells. Induction was normalized against the induction control, whose results were assigned a value of 100%. The data represent results of three independent
experiments performed in duplicate (n  6), presented as fold induction means  SEM. (B) Western blot of V5-tagged NSs proteins in the biological IFN assay.
(C) Western blot showing phosphorylation of IRF3 at Ser386 in HEK293T cells transfected with 250 ng untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins
and induced by cotransfection of a plasmid encoding the N terminus of RIG-I. Blots shown for IRF-3, -actin, and the V5 tag were blotted on the same
membrane, with two lanes removed (indicated by the separation in the ﬁgure; uncropped images can be found in Fig. S4). (D) Western blot of monomeric and
dimeric forms of IRF-3 in HEK293T cells cotransfected with 250 ng untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins and induced by cotransfection
of a plasmid encoding the N terminus of RIG-I. At 24 h posttransfection, the cell monolayer was lysed with nonreducing lysis buffer and the proteins were
separated on a nonreducing gel before Western blotting and probing with IRF-3, actin, and the V5 tag antibodies was performed.
Rezelj et al.
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[RIG-I N], MAVS, TBK1, IKK, or a phosphomimetic, active form of IRF-3 [IRF-3 5D]) were
overexpressed in HEK293T cells to examine the activation of the IFN- promoter in the
presence of untagged or V5-tagged UUKV, HRTV, or SFTSV NSs. For UUKV NSs, inhibi-
tion was observed only in the MAVS induction reporter assay (Fig. 3B) and not in the
RIG-I N, TBK1, IKK, or IRF-3 5D induction assays (Fig. 3A and C to E). As RIG-I is involved
in the activation of MAVS, the lack of inhibition by UUKV NSs at the level of RIG-I
(Fig. 3A) despite its inhibition of MAVS-induced IFN- promoter activation (Fig. 3B) was
surprising. It is possible that the overexpression of RIG-I N allows the detection of an
inhibitory effect of UUKV NSs on IFN production in a biological IFN assay (Fig. 2A)
whereas measurement of luciferase activity upon the transactivation of the murine
FIG 3 UUKV NSs protein inhibits IFN- induction at the level of MAVS, whereas HRTV NSs antagonizes at the level of TBK1. (A to E) HEK293T cells were
cotransfected with a Fireﬂy luciferase reporter plasmid under the control of an IFN- promoter and a Renilla luciferase control plasmid in the presence of
untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins. The cells were stimulated by cotransfection of inducer plasmids encoding FLAG-tagged RIG-I N (A),
MAVS (B), TBK1 (C), or IB kinase  (IKK) (D) or by cotransfection of a plasmid expressing untagged IRF3-5D (E). Fold induction was obtained by normalizing
the luciferase values to the nonstimulated mock control sample values. Western blots of transfected cell lysates are shown in the lower panels. The data
represent results of three independent experiments performed in duplicate (n  3), presented as fold induction means  SD. Statistical signiﬁcance for the
comparison of means between groups was determined by one-way ANOVA followed by Dunnett’s multiple-comparison post hoc tests. ****, P  0.0001; ***,
P  0.001; **, P  0.01; *, P  0.05.
TiBo Phlebovirus Innate Immune Antagonism
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IFN- promoter saturates the weak inhibitory effect of UUKV NSs at the level of RIG-I N
(Fig. 3A). A small increase in IFN production was detected upon transfection of RIG-I N
and UUKV NSs or NSs-V5; however, this increase was not signiﬁcant and was within the
limits of experimental variation within the system.
Transactivation of the IFN- promoter was inhibited by HRTV NSs and SFTSV NSs
upon stimulation by RIG-I N, MAVS, and TBK1 (Fig. 3A to C) but not by downstream
factors IKK and IRF-3 5D (Fig. 3D and E). While 99.7% inhibition of TBK1-induced
activation of the IFN- promoter by untagged and V5-tagged SFTSV NSs was observed,
only 43% inhibition by untagged and V5-tagged HRTV NSs was observed (Fig. 3C). Of
note, the difference in the levels of efﬁciency of antagonism of TBK1-induced IFN-
promoter activation may be explained by the fact that the levels of HRTV NSs expres-
sion were lower than the levels of SFTSV NSs expression, as detected by Western
blotting of transfected cell lysates (Fig. 3C). Our data suggest that UUKV NSs inhibits IFN
production at the level of MAVS, whereas HRTV NSs inhibits RIG-I N-, MAVS-, and
TBK1-induced IFN- reporter activity.
UUKV NSs antagonizes IFN induction through a direct interaction with MAVS.
We investigated whether the ability of UUKV NSs to inhibit IFN induction was due to a
direct interaction with effectors of the IFN induction pathway. HEK293T cells were
cotransfected with V5-tagged UUKV NSs and each of the FLAG-tagged IFN induction
components or untagged IRF-3 5D, and the cell lysates were subjected to coimmuno-
precipitation (co-IP) using anti-FLAG or anti-IRF-3 antibodies 18 h posttransfection.
UUKV NSs was coimmunoprecipitated only with FLAG-tagged RIG-I N and MAVS and
not with TBK1, IKK, or IRF-3 5D (Fig. 4A). As a control, we conﬁrmed that no V5-tagged
NSs was pulled down from transfected cells during co-IP using anti-FLAG beads or
anti-IRF-3 antibody (Fig. S2). RIG-I can interact with MAVS through its N-terminal 2CARD
domain (44, 45). Thus, to ensure that the pulldown of UUKV NSs with RIG-I N or MAVS
was not due to indirect interactions, we carried out reverse co-IPs. HEK293T cells
transiently expressing V5-tagged UUKV NSs and FLAG-tagged RIG-I N or MAVS were
subjected to co-IP with an anti-V5 antibody. Under these conditions, FLAG-tagged
MAVS, but not FLAG-tagged RIG-I N, could be coimmunoprecipitated in the presence
of V5-tagged UUKV NSs (Fig. 4B). These results were also conﬁrmed in the context of
UUKV infection. HEK293T cells were infected with UUKV at a high MOI (20 FFU/cell) for
8 h, followed by transient expression of FLAG-tagged RIG-I N or MAVS. At 30 h p.i., cell
lysates were subjected to immunoprecipitation using an anti-UUKV NSs antibody. While
no RIG-I N was coimmunoprecipitated with UUKV NSs (Fig. 4C, left panel), a weak band
was observed for MAVS (Fig. 4C, right panel). The detection of a weak signal for MAVS
(detectable only upon long exposure of the membrane), relative to the expression
levels detected in the whole-cell lysate, suggested a weak interaction between UUKV
NSs and MAVS.
Next, we examined whether UUKV NSs and MAVS could colocalize to conﬁrm our
co-IP and reporter assay data. We overexpressed FLAG-tagged MAVS together with
V5-tagged UUKV NSs in HEK293T cells. Following its activation, MAVS has been re-
ported to adopt a speckled staining pattern (46). Expression of V5-tagged UUKV NSs
exhibited the characteristic punctate, cytoplasmic staining described above (Fig. 1A
and D). We found that overexpression of FLAG-tagged MAVS in HEK293T cells resulted
in the distinct speckled staining characteristic of the active form of MAVS (Fig. 4D).
Although colocalization of UUKV NSs and MAVS was not obvious in some cells, close
examination revealed partial colocalization of the UUKV NSs punctate staining with
MAVS speckles (Fig. 4D). Partial colocalization of UUKV NSs with MAVS agrees with our
proposed hypothesis that the interaction between MAVS and UUKV NSs is weak, which
could explain its weak IFN-antagonistic activity.
HRTV NSs antagonizes IFN induction through a direct interaction with TBK1. To
elucidate the interacting partners of HRTV NSs, we took an approach similar to the one
taken for UUKV NSs. Cotransfection of V5-tagged HRTV NSs and each of the FLAG-
tagged IFN induction components resulted in the co-IP of HRTV NSs in the presence of
TBK1 only (Fig. 5A). Similar results were observed for SFTSV NSs, as previously reported
Rezelj et al.
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FIG 4 UUKV NSs interacts with MAVS. (A) HEK293T cells were cotransfected with a V5-tagged UUKV NSs-encoding plasmid along with FLAG-tagged RIG-I (N)
MAVS, TBK1, IKK, or untagged IRF3-5D-encoding plasmids. Transfected cell lysates were subjected to coimmunoprecipitation (co-IP) with beads conjugated
to FLAG or IRF3 antibodies. V5-tagged UUKV NSs was detected through Western blotting with an anti-V5 antibody. (B) Reverse co-IP. HEK293T cells were mock
transfected or transfected with V5-tagged UUKV NSs and FLAG-tagged RIG-I N (left panel) or MAVS (right panel). Cell lysates were subjected to co-IP with an
(Continued on next page)
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(Fig. S3) (30, 31). In the context of a virus infection, endogenous TBK1 was also
coimmunoprecipitated with HRTV NSs (Fig. 5B). The interaction observed in transfected
and infected cells also correlates with the inhibitory effect of HRTV NSs observed in our
luciferase reporter assays (Fig. 3).
TBK1 activation is achieved through phosphorylation of Ser172 (pTBK1) within its
classical kinase activation loop by the action of IKK. Furthermore, TBK1 can also
autophosphorylate at Ser172, leading to its activation when overexpressed in HEK293T
cells (47–50). Thus, we investigated whether HRTV or SFTSV NSs could prevent the
activation of TBK1 by inhibiting its phosphorylation at Ser172, thereby blocking IFN
induction. HEK293T cells were induced by a plasmid encoding FLAG-tagged TBK1 in the
presence of 250 ng of untagged or V5-tagged NSs proteins and were subsequently
harvested for analysis of TBK1 phosphorylation. TBK1 phosphorylated at Ser172 could
be readily detected in the mock cells stimulated with TBK1 (Fig. 5C). Reduced levels of
phosphorylated TBK1 were observed in the presence of HRTV or SFTSV NSs. However,
the block in phosphorylation appeared to be greater in the presence of SFTSV NSs than
in the presence of HRTV NSs whereas the levels of total TBK1 remained unchanged
under all experimental conditions. Of note, the difference in the levels of efﬁciency of
antagonism of TBK1 phosphorylation could once again be explained by the levels of
HRTV NSs expression being lower than those of SFTSV NSs expression, as detected by
Western blotting of transfected cell lysates (Fig. 5C).
We examined the subcellular localization of TBK1 in the presence or absence of
HRTV or SFTSV NSs in HEK293T cells. On its own, TBK1 showed cytoplasmic staining
(Fig. 5D). There was a clear sequestration of TBK1 to the inclusion bodies in SFTSV
NSs-transfected cells, as previously described by several groups. However, in cells
transiently expressing HRTV NSs, TBK1 remained cytoplasmic but colocalized with the
HRTV NSs signal (Fig. 5D). Interestingly, despite exhibiting very different cellular local-
ization, the strategy by which the antagonistic function of HRTV NSs occurs appears to
mirror that of SFTSV, i.e., blocking the phosphorylation and hence activation of TBK1.
Thus, our ﬁndings suggest that HRTV NSs and SFTSV NSs share some key characteristics:
IFN antagonist activity and interaction with TBK1.
HRTV and SFTSV, but not UUKV NSs, impair type I IFN signaling through an
interaction with STAT2 but do not inhibit type II IFN signaling. To assess whether
UUKV and HRTV NSs could inhibit type I IFN signaling, we transfected HEK293T cells
with a reporter plasmid encoding luciferase under the control of an interferon-
stimulated response element (ISRE) promoter along with constructs expressing the viral
NSs proteins, using SFTSV NSs as a control, as SFTSV NSs has been shown to act as a
potent antagonist of IFN signaling (30–34). Interestingly, UUKV NSs was unable to
abrogate type I IFN signaling. In comparison, HRTV NSs and SFTSV NSs exhibited a
strong inhibitory effect on ISRE promoter activation (Fig. 6A). As already noted, expres-
sion of HRTV NSs was lower than that of UUKV NSs or SFTSV NSs in these assays, which
was demonstrated by Western blotting of the cell lysates transfected with V5-tagged
NSs proteins (Fig. 6B).
Other published data show that SFTSV NSs directly interacts with and sequesters
STAT1 and STAT2 into inclusion bodies to block type I IFN signaling (33, 34). To
investigate whether HRTV NSs was also capable of these interactions, we performed
immunoprecipitation of transfected V5-tagged NSs proteins (Fig. 6C). In agreement
with our reporter assay, no interaction between UUKV NSs and STAT1 or STAT2 was
FIG 4 Legend (Continued)
anti-V5 antibody. FLAG-tagged RIG-I N and MAVS in the co-IP eluates were detected by Western blotting with an anti-FLAG antibody. (C) co-IP of UUKV NSs
upon UUKV infection in the presence of FLAG-tagged RIG-I N or MAVS. HEK293T cells were mock infected or infected with UUKV at a high MOI (20 FFU/cell)
for 8 h, followed by mock transfection or transfection of FLAG-tagged RIG-I N-encoding plasmids (left panel) or MAVS-encoding plasmids (right panel). At 30 h
p.i., the cell lysates were subjected to co-IP using an anti-UUKV NSs antibody, followed by detection of FLAG-tagged RIG-I N or MAVS and UUKV NSs by Western
blotting. (D) Subcellular localization of UUKV NSs-V5 and FLAG-tagged MAVS. HEK293T cells were mock transfected or transfected with UUKV NSs-V5 or
FLAG-tagged MAVS or both. At 24 h posttransfection, the cells were ﬁxed, permeabilized, and probed with V5 (red) and FLAG (green) antibodies. DAPI-stained
nuclei (blue) and subcellular localization of the proteins were analyzed by confocal microscopy. Intensity proﬁle graphs are shown at the bottom of the image
(x axis, distance [in micrometers]; y axis, intensity). Scale bars indicate 10 m. IP, immunoprecipitation; WB, Western blotting; WCL, whole-cell lysate.
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observed. Like SFTSV NSs, endogenous STAT1 and STAT2 were coimmunoprecipitated
with HRTV NSs, suggesting that the IFN signaling interacting partners of these two
proteins are conserved (Fig. 6C). Interestingly, STAT2 levels in IP eluates were higher
than those of STAT1 (relative to the respective total expression levels in the whole-cell
lysate). Indeed, a longer exposure was required to detect STAT1 in immunoprecipitated
samples, suggesting that the interaction of HRTV NSs or SFTSV NSs with STAT2 is
FIG 5 HRTV NSs interacts with TBK1. (A) HEK293T cells were cotransfected with a V5-tagged HRTV NSs-encoding plasmid along with FLAG-tagged RIG-I (N),
MAVS, TBK1, or IKK or untagged IRF3-5D-encoding plasmids. Transfected lysates were subjected to coimmunoprecipitation with beads conjugated to FLAG
or IRF3 antibodies. V5-tagged HRTV NSs was detected through Western blotting with an anti-V5 antibody. (B) Immunoprecipitation of HRTV NSs in infected cells.
Cell lysates of A549 cells infected with HRTV (MOI 10 FFU/cell) were subjected to immunoprecipitation with an anti-HRTV NSs antibody. Western blotting was
performed on IP eluates to detect the presence of TBK1 and HRTV NSs in HRTV-infected cells. (C) HEK293T cells were cotransfected with plasmids expressing
untagged or V5-tagged HRTV or SFTSV NSs and FLAG-tagged TBK1 to induce interferon induction. At 24 h posttransfection, cell lysates were harvested and
utilized for Western blotting of TBK1, TBK1 phosphorylated at Ser172, tubulin, and V5 with the appropriate antibodies. WB, Western blot. (D) Indirect
immunoﬂuorescent staining of HEK293T cells transiently expressing TBK1-FLAG and V5-tagged HRTV or SFTSV NSs and probed with anti-TBK1 and anti-V5
antibodies 24 h posttransfection. Subcellular localization of NSs proteins (red), TBK1 (green), and nuclei stained with DAPI (blue) was analyzed by confocal
microscopy. Intensity proﬁle graphs are shown to the right of the image. Scale bars indicate 20 m.
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stronger than that with STAT1. It is also possible that STAT1-STAT2 heterodimers are
precipitated in the presence of HRTV and SFTSV NSs proteins and therefore that the
precipitated STAT1 is not a result of a direct interaction with the NSs proteins but is
rather a result of an indirect interaction through STAT2.
STAT3 is a pleiotropic STAT that has been implicated in modulating inﬂammatory
responses in type I IFN signaling (51) as well as in regulating T cell proliferation by
preventing apoptosis (52) and CD4 and CD8 T cell survival and differentiation (53,
54). With this in mind, we also investigated whether the NSs proteins of tick-borne
phleboviruses would interact with STAT3. No STAT3 was pulled down following immu-
noprecipitation of V5-tagged proteins (Fig. 6D).
The ultimate translocation of STAT1 and STAT2 proteins to the nucleus to activate
the promoter of ISGs occurs via their phosphorylation and dimerization (55, 56). While
one study has shown that only STAT2 (but not STAT1) phosphorylation is inhibited by
SFTSV NSs (34), another study has shown that the phosphorylation of STAT2 as well as
of STAT1 at position Ser727 is blocked by SFTSV NSs (33). We examined the ability of
HRTV or SFTSV NSs to inhibit STAT1 or STAT2 phosphorylation using UUKV NSs as a
negative control, as UUKV NSs did not block type I IFN signaling (Fig. 6A). HEK293T cells
transiently expressing untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins were
treated with recombinant IFN- for 30 min, and the cell lysates were harvested for
Western blotting 24 h posttransfection. Unlike Chaudhary et al. (33), we observed no
difference in the levels of STAT1 or phosphorylated STAT1 (at position Ser727 or
position Tyr701) in the presence of SFTSV NSs compared to the mock control. Similar
results were observed for UUKV and HRTV NSs proteins (Fig. 6E). While in the presence
of the tick-borne Phlebovirus NSs proteins STAT2 levels also remained unchanged
compared to those seen with the mock control, we observed a reduction in the levels
of STAT2 phosphorylation (position Tyr690) in the presence of HRTV and SFTSV NSs
proteins compared to the levels found in the mock control and the UUKV NSs-
transfected controls (Fig. 6E).
We next sought to compare the effect of HRTV NSs on the translocation of STAT1
and STAT2 to the nucleus upon IFN stimulation to that of SFTSV NSs. To do this, we
used HeLa cells, which have been utilized previously to visualize the sequestration of
STAT1 and STAT2 into SFTSV NSs-formed inclusion bodies (33). HeLa cells transiently
expressing V5-tagged HRTV or SFTSV NSs were treated with IFN- for 30 min at 24 h p.t.
prior to analysis with V5 and STAT1 or STAT2 antibodies. Although STAT1 was seques-
tered into the characteristic inclusion bodies in cells transiently expressing SFTSV NSs,
its translocation to the nucleus due to IFN- stimulation was not completely inhibited,
as nuclear STAT1 could also be detected (Fig. 6F). Expression of HRTV NSs did not result
in an accumulation of STAT1 into inclusion bodies as noted for SFTSV; instead, STAT1
appeared diffused throughout the cytoplasm, as well as in the nucleus (Fig. 6F). In
contrast to what was observed with STAT1, no nuclear translocation of STAT2 was
detected in cells transiently expressing V5-tagged HRTV or SFTSV NSs upon IFN
treatment (Fig. 6G). As with TBK1, STAT2 remained diffused in the cytoplasm in the
FIG 6 HRTV and SFTSV NSs, but not UUKV NSs, inhibits JAK/STAT IFN signaling. (A) ISRE reporter assay in the presence of tick-borne Phlebovirus NSs
proteins. HEK293T cells were transfected with a Fireﬂy luciferase reporter plasmid under the control of an ISRE promoter and a Renilla luciferase control
plasmid in the presence of the indicated amounts of untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins. The cells were stimulated with IFN-
(500 U/ml) 24 h posttransfection and lysed 18 h later for analysis. Induction was normalized against the induction control, whose results were assigned
a value of 100%. The data represent results of three independent experiments performed in duplicate (n  3), presented as fold induction means 
SEM. RLU, relative light units. (B) Western blots of transfected cell lysates. (C and D) Cell lysates from HEK293T cells transiently expressing V5-tagged
UUKV, HRTV, or SFTSV NSs were immunoprecipitated with an anti-V5 antibody and analyzed by Western blotting with STAT1 and STAT2 antibodies (C)
or with a STAT3 antibody (D). (E) Phosphorylation of STAT1 and STAT2 in HEK293T cells upon treatment with recombinant IFN-. HEK293T cells
transiently expressing untagged or V5-tagged UUKV, HRTV, or SFTSV NSs were treated with recombinant IFN- 24 h posttransfection. Upon 30 min of
IFN- treatment, the cell lysates were harvested and utilized for Western blotting of STAT2, STAT2 phosphorylated at Tyr690, STAT1, STAT1
phosphorylated at Ser727 or Tyr701, actin, and V5 with the appropriate antibodies. (F and G) HeLa cells were transfected with plasmids encoding
V5-tagged HRTV or SFTSV NSs. At 24 h posttransfection, the cells were treated with IFN- (1,000 U/ml) for 30 min, ﬁxed, permeabilized, and probed with
(V5) STAT1 (F) and STAT2 (G) antibodies to visualize the subcellular localization of endogenous STATs (red), V5-tagged NSs (green), and DAPI-stained
nuclei (blue) by confocal microscopy. Scale bars indicate 20 m. (H) HEK293T cells transiently expressing untagged or V5-tagged UUKV, HRTV, or SFTSV
NSs proteins were treated with 50 ng IFN-. At 24 h posttreatment, total cellular RNA was isolated and subjected to RT-qPCR to examine mRNA levels
of IP-10 and CXCL10. Fold increase was derived by normalizing relative mRNA levels of the target to GAPDH mRNA levels using a ΔΔCT method.
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presence of HRTV NSs, in comparison to a clear sequestration into the inclusion bodies
formed by SFTSV NSs. Thus, these results indicate that the interaction of HRTV NSs or
SFTSV NSs protein with STAT2 (but not STAT1) results in the efﬁcient inhibition of
IFN--induced STAT2 nuclear translocation. Perhaps the leakage of STAT1 into the
nucleus in the presence of HRTV NSs or SFTSV NSs following IFN- treatment is a result
of a weak (or indirect) interaction between the NSs proteins and STAT1, as noted from
our co-IP experiments.
As type II IFN signaling is mediated by STAT1 homodimers, we investigated whether
the weak or indirect interaction of HRTV and SFTSV NSs with STAT1 could result in an
inhibitory effect upon type II IFN signaling. mRNA levels of two IFN--induced ISGs
(IRF-1 and CXCL10) were investigated following IFN- treatment of HEK293T cells
transiently expressing HRTV or SFTSV NSs proteins, using UUKV NSs as a control
(Fig. 6H). No effect was observed on mRNA levels of IRF-1 and CXCL10 in cells
transiently expressing UUKV, HRTV, or SFTSV NSs proteins following IFN- treatment.
This ﬁnding suggests that the interaction of HRTV and SFTSV NSs with STAT1 does not
inhibit type II IFN signaling.
To summarize, our results indicate that impairment of type I IFN signaling by HRTV
and SFTSV NSs occurs mainly in a STAT2-dependent manner, whereas no impairment
of IFN signaling by UUKV NSs was detected. Additionally, only the phosphorylation and
nuclear translocation of STAT2 are efﬁciently impaired by HRTV and SFTSV NSs proteins
upon IFN- treatment. These observations suggest that both HRTV and SFTSV NSs
proteins have a conserved direct interaction with STAT2 which enables the proteins to
efﬁciently antagonize type I IFN signaling (Fig. 6A). On the other hand, their weak or
indirect interaction with STAT1 does not enable HRTV and SFTSV NSs proteins to inhibit
type II IFN signaling (Fig. 6H).
Comparison of the levels of TiBo Phlebovirus sensitivity to the interferon
response. Different strains of mosquito-borne Rift Valley fever virus (RVFV) exhibit
differential sensitivities to the action of IFN depending on the capacity of the NSs
proteins of the various strains to efﬁciently block the type I IFN response (57). To
investigate the sensitivity of tick-borne phleboviruses to virus-induced IFN, we exam-
ined the effect of a JAK1/2 inhibitor, ruxolitinib (previously described in reference 58),
on focus formation. While UUKV foci were undetectable in A549 cells, treatment with
ruxolitinib restored the ability of UUKV to form foci in these cells (Fig. 7A). In contrast,
ruxolitinib treatment had no signiﬁcant effect on HRTV focus size. Unexpectedly, and
even though the SFTSV genome encodes an NSs protein that is a potent inhibitor of the
IFN system (30–34), we observed a signiﬁcant increase in SFTSV focus size in A549 cells
treated with ruxolitinib (Fig. 7A). Thus, despite encoding a potent IFN antagonist, SFTSV
infection still results in IFN induction (Fig. 7G), thereby limiting virus infection in
neighboring cells. To ensure that this effect was not due to the presence of defective
interfering particles in our SFTSV stock, the virus was subjected to plaque puriﬁcation.
Four different newly plaque-puriﬁed SFTSV stocks yielded results similar to those
obtained with our laboratory SFTSV stock (data not shown).
To corroborate the results obtained with ruxolitinib treatment, the growth kinetics
of UUKV, HRTV, and SFTSV were compared at a low MOI and a high MOI (0.1 FFU/cell
and 3 FFU/cell, respectively) in A549 cells. At the indicated time points, cell culture
supernatants were harvested, virus titers were determined, and the relative amounts of
IFN produced were quantiﬁed through biological IFN assays. The ﬁndings presented in
Fig. 7B to G support the results obtained by measuring IFN sensitivity using ruxolitinib
treatment. At the low MOI, infection with UUKV and SFTSV resulted in mean peak titers
of 2  104 FFU/ml and 8.2  105 FFU/ml at 72 h p.i., respectively, approximately 1-log
lower than the titers seen when cells were infected at the high MOI (Fig. 7B and D).
While UUKV infection induced IFN by 24 h p.i. following the high-MOI infection, no IFN
could be detected at the low MOI (Fig. 7E). The lack of IFN production by UUKV at the
low MOI could be explained by the low replication levels seen throughout the time
course, as only a 1-log increase in virus titer was observed by 72 h p.i. On the other
hand, faster growth kinetics exhibited by SFTSV (a 3-log increase in virus titer) resulted
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in increased induction of IFN by SFTSV at the low MOI (Fig. 7G). In contrast to UUKV and
SFTSV, the high and low MOI growth curves of HRTV showed similar mean titers by 72 h
p.i. (at the low MOI, 1.7  105 FFU/ml; at the high MOI, 3.3  105 FFU/ml) (Fig. 7D).
Furthermore, even at the high MOI, HRTV infection resulted in very little induction of
IFN (4 relative IFN units [RIU]) by 72 h p.i. (Fig. 7F). Though surprising, our data showing
the induction of IFN by SFTSV despite its being equipped with a potent antagonist of
the IFN system agree with a recent study. That study demonstrated that sera from
SFTSV-infected patients showed high concentrations of IFN- compared to sera from
healthy patients and that the concentration of IFN- in patients with severe SFTSV was
signiﬁcantly higher than that in patients with mild SFTS (59).
Taken together, these data demonstrate that UUKV and SFTSV cannot efﬁciently
antagonize IFN production during infection and that induction of IFN leads to reduced
spread of the virus to neighboring cells. On the other hand, we show that HRTV can
limit IFN production following infection.
FIG 7 Sensitivity of tick-borne phleboviruses to IFN. (A) Focus-forming assays of UUKV, HRTV, and SFTSV on A549 cells 6 days p.i. The overlay was supplemented
with JAK/STAT inhibitor ruxolitinib (0.4 M) or the equivalent volume of the vehicle control DMSO. Foci were detected using anti-UUKV, HRTV, or SFTSV N
antibodies. (B to D) Growth curves of UUKV (B), HRTV (C), or SFTSV (D) at a low MOI (0.1 FFU/cell) and a high MOI (3 FFU/cell) in A549 cells. The cell culture
supernatant of triplicate wells was collected at the indicated time points, and virus titers were determined through focus-forming assays. *, P  0.05. (E to G)
Samples from the experiments described for panels B to D were subjected to UV inactivation, and the relative IFN units were quantiﬁed through a biological
IFN assay. Error bars indicate SD of the means. The results shown in this ﬁgure are representative of 2 experimental repeats.
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DISCUSSION
Phleboviruses have a trisegmented negative or ambisense RNA genome that can
activate IFN induction by the stimulation of RIG-I. Induction of type I IFN at an early
stage following virus infection can have protective effects against virus infection, which
is best illustrated by the high susceptibility of type I IFN receptor knockout mice to virus
infection compared to wild-type mice (57, 60, 61). Consequently, phleboviruses require
efﬁcient mechanisms to antagonize the IFN response. Recent reviews have highlighted
the importance of elucidating the countermeasures employed by phleboviruses to
hinder the IFN response (62, 63). These recommendations come with the realization
that, until the recent emergence of highly pathogenic SFTSV, most studies focused on
the ability of the NSs protein of mosquito-borne phleboviruses, in particular, RVFV NSs
protein, to overcome the IFN system. However, unlike most other Phlebovirus NSs
proteins, RVFV NSs localizes to the nucleus, forming unique ﬁlamentous structures in
the nuclei of infected cells (64–68). Part of the IFN-antagonistic activity of RVFV NSs is
attributed to its nuclear localization, which allows it to suppress host cell transcription
generally but also IFN- mRNA synthesis speciﬁcally (69–71). RVFV NSs has also been
implicated in preventing the inhibition of translation by the proteasome-dependent
downregulation of double-stranded RNA-dependent protein kinase (PKR) (72–76). Like
RVFV, the NSs protein of mosquito-borne Toscana virus (TOSV) can induce proteasome-
mediated degradation of PKR (77), but it can additionally inhibit the production of IFN
through a direct interaction with RIG-I (78, 79). The NSs protein of Punta Toro virus (PTV;
also mosquito-borne) acts as a suppressor of the IFN response by inhibiting host cell
transcription like RVFV NSs but does not affect PKR levels (77, 80).
With the emergence of SFTSV in China and the discovery of HRTV in the United
States, there is now a pressing need to understand the molecular mechanisms of
virulence of these pathogens and those of other previously described and neglected
tick-borne phleboviruses. The discovery that SFTSV NSs forms unique cytoplasmic
inclusion bodies which act to sequester elements from the IFN induction and IFN
signaling pathways suggested that Phlebovirus NSs proteins have evolved highly
divergent mechanisms to counteract the human IFN response (30–34, 81). This is
underscored by the fact that within the Phlebovirus genus, the NSs protein sequence
has extremely low conservation at the amino acid level in comparison to the other viral
proteins (5).
In this report, we highlight the diverse mechanisms that tick-borne Phlebovirus NSs
proteins employ to antagonize the IFN response, by demonstrating that UUKV NSs and
HRTV NSs utilize strategies different from those employed by the well-studied SFTSV
NSs to subvert this powerful antiviral response. The proposed model of tick-borne
Phlebovirus NSs antagonism of the IFN response is summarized in Fig. 8. Our reporter
assays showed that the NSs protein of apathogenic UUKV acts as a weak antagonist of
IFN induction, but not of IFN signaling, which agrees with our previous studies (35)
(Fig. 2 and 6). This is in comparison to the strong inhibition of IFN- and ISRE promoter
activation seen with the NSs proteins belonging to the more pathogenic HRTV and
SFTSV. As UUKV has been associated with infection in birds (14, 82, 83), it would be of
interest to investigate in future studies whether its NSs protein has adapted to
antagonize the avian innate immune system with higher efﬁciency than was seen with
the human innate immune system tested here. Our reporter assays and coimmuno-
precipitation studies further demonstrated that the molecular mechanism regulating
the inhibition of IFN induction by UUKV NSs likely operates through a direct interaction
with MAVS, an effector protein involved in the early stages of the IFN induction
pathway (Fig. 3 and 4). Examination of this interaction through confocal microscopy
studies revealed that some punctate cytoplasmic structures of UUKV NSs colocalize
with speckle-like structures formed by MAVS (Fig. 4D), which may inhibit MAVS
activation and downstream signaling of IFN induction. Toscana virus (TOSV) NSs protein
has also been shown to inhibit the induction of type I IFN at early stages of the IFN
induction pathway by targeting RIG-I for proteasomal degradation (78). The inﬂuenza
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A virus PB1-F2 protein has also been shown to suppress IFN induction by binding to
MAVS and altering the mitochondrial membrane potential (84, 85), which is required for
MAVS-mediated IFN induction (86). Studies are in progress to understand whether
UUKV NSs utilizes mechanisms to suppress IFN induction that are similar to those
described for inﬂuenza virus PB1-F2 protein. As it stands, and to our knowledge,
targeting MAVS to antagonize the type I IFN response is a novel strategy described for
Phlebovirus NSs proteins.
Our results show, for the ﬁrst time, that HRTV NSs acts as a potent antagonist of both
IFN induction and type I IFN signaling (Fig. 2 and 6). Reporter assays and co-IP
experiments enabled us to determine that the ability of HRTV NSs to block IFN
induction and type I IFN signaling is facilitated through a direct interaction with TBK1
and STAT2, respectively (Fig. 5 and 6). Despite HRTV NSs sharing only 63% amino acid
FIG 8 Schematic summary of the mechanisms by which tick-borne Phlebovirus NSs proteins inhibit the canonical IFN induction and signaling pathways.
Following bunyavirus infection, the generation of ssRNA with uncapped 5= triphosphate ends during uncoating, transcription, or replication results in ssRNA
binding to the RNA helicase RIG-I. RIG-I is activated in turn, and exposure of its two associated CARD domains allows the recruitment of the adaptor MAVS
through two CARD-CARD interactions. Activation of MAVS leads to the subsequent activation of kinases such as TBK1 and/or IKK, which leads to concomitant
phosphorylation of IRF3 at speciﬁc serine residues. (A) Phosphorylation of IRF3 leads to its dimerization and translocation to the nucleus, where IRF3 dimers
ultimately stimulate transcription of genes under the control of the IFN-/ promoter, resulting in the production of IFN-/. (B) Signal transduction of type
I IFNs initiates through the binding of secreted IFN-/ to type I IFN receptors (a heterodimer of IFNAR1 and IFNAR2) and the activation of multiple downstream
signaling pathways. Signal transduction of type I, II, and III IFN initiates through the binding of secreted IFN to the respective IFN receptors and the activation
of multiple downstream signaling pathways. Type I and type III IFN signaling pathways are mainly mediated via STAT1-STAT2 heterodimers. Receptor-associated
kinases JAK1 and TYK2 become activated and phosphorylate STAT1 and STAT2, respectively. Phosphorylated STATs can heterodimerize and recruit IRF9 for the
assembly of the heterotrimer complex ISGF3. ISGF3 translocates to the nucleus and binds to ISRE, leading to the induction of many IFN-stimulated genes (ISG).
Type III IFN signaling is more commonly associated with signaling by homodimerization of STAT1, which can translocate to the nucleus and activate GAS
promoters, also initiating ISG transcription. Tick-borne Phlebovirus NSs proteins have evolved several countermeasures to block the IFN pathway. SFTSV NSs (red)
directly interacts with and sequesters TBK1 and STAT2 into inclusion bodies to spatially isolate these elements. Additionally, through its interaction with TBK1
and STAT2, SFTSV NSs can also indirectly sequester IKK, IRF-3, and STAT1 into the inclusion bodies. An interaction between SFTSV NSs and TRIM-25 also
facilitates the spatial isolation of RIG-I, in an indirect manner. HRTV NSs (yellow) can also block IFN induction through a direct interaction with TBK1 and block
IFN signaling by a direct interaction with STAT2. However, as HRTV NSs does not form inclusion bodies as SFTSV NSs does, its mechanism of antagonism is
different from that of SFTSV NSs. UUKV NSs (green) blocks IFN induction only, targeting MAVS. For references, see the text. Dashed red lines indicate indirect
interactions. Solid red lines indicate direct interactions. For references, see the text. CARD, caspase recruitment domain; GAS, gamma-activated sequence; IFNAR,
interferon-/ receptor; IFNGR1, interferon gamma receptor 1; IB, inhibitor of kappa B; IKK, inhibitor of nuclear factor kappa-B kinase subunit alpha; IKK ,
inhibitor of nuclear factor kappa-B kinase subunit beta; IKK, IB kinase-; IRF, IFN-regulatory factor; ISGF3, IFN-stimulated gene factor 3; ISGs, IFN-stimulated
genes; ISRE, IFN-stimulated response elements; JAK1, Janus kinase 1; MAVS, mitochondrial antiviral signalling protein; NFB, nuclear factor kappa-light-chain
enhancer of activated B cells; RIG-I, retinoic acid-inducible gene I; STAT, signal transducer and activator of transcription; TBK1, TANK-binding kinase 1; TYK2,
tyrosine kinase 2.
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identity with SFTSV NSs, the interactions reported here are conserved with those of
SFTSV NSs, which also interacts with TBK1 and STAT2, antagonizing their phosphory-
lation to inhibit the IFN response (30, 31, 34). However, while SFTSV NSs spatially
isolates TBK1 and STAT2 into inclusion bodies, the interactions between HRTV NSs and
TBK1 and STAT2 were notably different in terms of subcellular localization, as these
proteins remained diffused in the cytoplasm in the presence of HRTV NSs (Fig. 5 and 6).
It was previously reported that the N-terminal PxxP motif (amino acid residues 66 to 69)
of SFTSV NSs is required for the formation of inclusion bodies (31). Simultaneous
substitution of Pro66 and Pro69 resulted in diffused cytoplasmic localization and
affected the IFN-antagonistic activity of SFTSV NSs. Surprisingly, the PxxP motif was
conserved in HRTV NSs (see Fig. S1 in the supplemental material), indicating that the
motif may be required but is not sufﬁcient for inclusion body formation and the IFN
antagonistic activity of NSs. Nonetheless, a direct interaction of HRTV NSs with TBK1 in
the cytoplasm, rather than sequestration to inclusion bodies, was sufﬁcient to prevent
its activation by blocking TBK1 phosphorylation of Ser172 and the subsequent phos-
phorylation of downstream factors.
In terms of IFN signaling, our co-IP assays demonstrated that HRTV and SFTSV NSs
could interact with both STAT1 and STAT2 (Fig. 6C). However, a stronger interaction
was observed with STAT2 than with STAT1. Additionally, IFN--induced phosphoryla-
tion and nuclear translocation of STAT2, but not STAT1, were efﬁciently inhibited in the
presence of HRTV or SFTSV NSs proteins (Fig. 6E to G).
In a manner similar to its interaction with TBK1, the mechanism by which SFTSV NSs
inhibits STAT1 and STAT2 translocation to the nucleus operates through their spatial
isolation in inclusion bodies (34). No spatial isolation of STAT1 or STAT2 was observed
in the presence of HRTV NSs, suggesting simply that an interaction between HRTV NSs
and STAT2 may block phosphorylation of STAT2 and its heterodimerization with STAT1,
consequently inhibiting the translocation of STAT1-2 heterodimers to the nucleus and
thus inhibiting type I and type III IFN signaling. It remains to be elucidated whether the
coimmunoprecipitation of STAT1 in the presence of HRTV and SFTSV NSs is due to an
indirect interaction through the precipitation of STAT1-2 heterodimers or simply to a
weak interaction. As it stands, the weak interaction or lack of direct interaction with
STAT1 may play a role in the differential regulation of type I and type II IFN signaling
by HRTV and SFTSV NSs. In canonical type I IFN signaling, STAT1-STAT2 heterodimers,
in association with IRF-9, translocate to the nucleus and bind to ISREs. Under conditions
of activation through type I or type II IFN, STAT1 can also form homodimers, which
translocate to the nucleus to activate gamma-activated site (GAS) elements. Activation
of GAS elements by STAT1 homodimers results in the production of proinﬂammatory
cytokines, such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and P40, which can
cause severe disease (87). Our results indicate that HRTV and SFTSV NSs proteins are
unable to inhibit type II IFN signaling (Fig. 6H), an observation which is supported by
our data showing a weak interaction or a potential lack of direct interaction between
these proteins and STAT1 as well as the inability of HRTV and SFTSV NSs proteins to
block the nuclear translocation of STAT1. Furthermore, STAT3, which has also been
implicated in modulating inﬂammatory responses (88), did not act as an interacting
partner for UUKV, HRTV, or SFTSV NSs. Therefore, our results indicate that HRTV NSs can
suppress type I IFN signaling through a direct interaction with STAT2 in a manner
different from that seen in the sequestration of STAT2 into SFTSV NSs inclusion bodies.
The weak interaction or lack of direct interaction of HRTV and SFTSV NSs with STAT1,
and the lack of an interaction with STAT3, could act as an explanation for the strong
cytokine-mediated inﬂammatory responses suggested to be responsible for disease
progression in SFTSV mouse models as well as in patients diagnosed with SFTS (89, 90)
and for the symptoms (identical to those seen in SFTS disease) that have been observed
in HRTV patients (9, 10).
The ﬁrst indication that the NSs protein of a Phlebovirus had an IFN antagonist role
was the ﬁnding that, in comparison to virulent RVFV strain ZH548, RVFV strains bearing
mutations in the NSs gene (MP12 and clone 13) induced IFN and were virulent in mice
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lacking the type I IFN receptor but not in wild-type mice (57). Thus, given that the
sensitivity of RVFV to IFN is dictated by the capacity of the virus NSs protein to
efﬁciently block the production of IFN following infection, we aimed to investigate the
sensitivity to IFN of the tick-borne phleboviruses used in this report. Our results show
that in IFN-competent A549 cells, the foci produced by UUKV were undetectable and
the foci produced by SFTSV were small (Fig. 7A). However, when IFN signaling was
impaired by addition of the JAK1/2 inhibitor ruxolitinib to the focus-forming assay
overlay, UUKV foci could be detected and SFTSV formed signiﬁcantly larger foci. These
data suggest that the IFN response mounted as a result of virus infection results in an
antiviral state in neighboring infected cells, which limits UUKV and SFTSV spread.
Similarly, the inability of UUKV and SFTSV to reach similar peak titers during infections
at low MOI and high MOI could be explained by the sensitivity of the viruses to induced
IFN, limiting virus replication. Notably, some differences were observed in the ability of
the viruses to interact with cells in an IFN-induced state. UUKV exhibited poor replica-
tion kinetics, presumably due to its inability to cope with the action of virus infection-
induced IFN (Fig. 7B and E). These results are in line with our previous ﬁnding that UUKV
NSs is a weak IFN antagonist (35), as the inability of UUKV to efﬁciently circumvent the
IFN response may be a result of the weak IFN-antagonistic activity of its NSs protein.
Comparatively, SFTSV exhibited faster replication kinetics throughout the time course
despite inducing more IFN, suggesting that SFTSV is less sensitive to the action of IFN
than UUKV (Fig. 7B, D, E, and G).
Other studies and the results described here suggested that the NSs protein of
SFTSV is a potent IFN antagonist. However, a recent report showed that sera from
SFTSV-infected patients show high concentrations of IFN- compared to sera from
healthy patients (59). Our results explain these observations and indicate that, despite
encoding a potent IFN antagonist (Fig. 2 and 6), in the context of a virus infection, the
amount of IFN induced during SFTSV infection is not completely overcome by the
action of its viral IFN antagonist (Fig. 7). Perhaps SFTSV has evolved such a potent IFN
antagonist to compensate for the generation of a large number of PAMPs during virus
replication that result in the rapid induction of the IFN response—an interesting
hypothesis and avenue for future studies. Interestingly, and in comparison to SFTSV, no
signiﬁcant difference was observed in HRTV focus size in A549 cells in comparisons of
functional and nonfunctional IFN signaling responses (Fig. 7A). Low- and high-MOI
HRTV infections resulted in similar peak titers, and little IFN was detected, suggesting
that the virus can efﬁciently control IFN production following infection, which the data
presented in the manuscript suggest is mediated by its NSs protein.
To conclude, our ﬁndings serve to expand our knowledge of the differential strat-
egies evolved by phleboviruses to modulate host innate immune responses and
highlight that, despite being poorly conserved in terms of amino acid sequence, the
NSs proteins of phleboviruses retain their IFN antagonistic function.
MATERIALS AND METHODS
Cells and viruses. A549, HeLa, and Vero E6 cells (commonly used cell lines originally obtained from
the European Collection of Authenticated Cell Cultures [ECACC] and previously described in references
64 and 91; Vero E6 cells were from Institut Pasteur) were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS). HEK293T cells (ECACC) were grown in DMEM
supplemented with 10% FCS and 0.1 mM MEM nonessential amino acids (NEAA). BSR cells (a variant of
BHK-21 cells; kindly provided by Karl-Claus Conzelmann) were grown in Glasgow’s MEM (GMEM)
supplemented with 10% tryptose phosphate broth (TPB) and 10% FCS. Cells were maintained at 37°C
with 5% CO2.
The wild-type UUKV strain used in this study was derived from the prototype S-23 strain and grown
in BSR cells as previously described (35, 92). HRTV (isolated from patient 2 as described in reference 9)
was a kind gift by R. Tesh (World Reference Centre for Emerging Viruses and Arboviruses, Galveston, TX).
The SFTSV strain used was a plaque-puriﬁed cell culture-adapted stock strain called Hubei 29pp (HB29pp)
provided by A. Lambert (CDC Arbovirus Diseases Branch, Division of Vector-Borne Infectious Diseases,
Fort Collins, CO) (93). Working stocks of HRTV and SFTSV were generated in Vero E6 cells by infection at
a low multiplicity of infection (MOI) and by harvesting the cell culture medium 7 days p.i. All experiments
performed with HRTV or SFTSV were conducted under containment level 3 (CL-3) conditions approved
by the UK Health & Safety Executive.
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Virus titration by plaque- or focus-forming assays. Virus titers were determined by focus-forming
assays in BSR cells for UUKV and by plaque assay in Vero E6 cells for HRTV and SFTSV. Brieﬂy, conﬂuent
monolayers of cells were infected with serial dilutions of virus made in phosphate-buffered saline (PBS)
containing 2% FCS and incubated for 1 h at 37°C, followed by the addition of a GMEM overlay
supplemented with 2% FCS and 0.6% Avicel (FMC Biopolymer). The cells were incubated for 6 days
before ﬁxation and staining with crystal violet was performed to visualize HRTV and SFTSV plaques or
using focus-forming assays for UUKV as described previously (35).
To investigate the effect of the JAK1/2 inhibitor ruxolitinib (Selleck Chemicals) on focus formation,
stocks were prepared at 10 mM in dimethyl sulfoxide (DMSO). Following virus infection of A549 cells, the
Avicel overlay was supplemented with 0.4 M ruxolitinib or the equivalent volume of the vehicle
control DMSO. Foci were detected using anti-UUKV, anti-HRTV, and anti-SFTSV nucleocapsid anti-
bodies (58, 93, 94).
Indirect immunoﬂuorescence staining. For studies involving the subcellular localization of NSs
proteins, HEK293T or A549 cells were grown to subconﬂuence on glass coverslips (13-mm diameter) and
infected at a high MOI (3 FFU or PFU/ml) with UUKV, HRTV, or SFTSV. At 24 h p.i., the cells were ﬁxed with
4% formaldehyde–PBS. Following permeabilization with 0.1% Triton X-100–50 mM glycine–PBS, proteins
were detected using rabbit anti-UUKV NSs (kindly provided by Anna Överby, Umeå University, Sweden),
rabbit anti-HRTV NSs (described below), rabbit anti-SFTSV NSs (93), and secondary anti-rabbit Alexa Fluor
488 (Thermo Fisher). For indirect immunoﬂuorescence staining of proteins following transfections,
HEK293T or HeLa cells seeded in poly-L-lysine-coated or uncoated glass coverslips were transfected with
the appropriate expression plasmids and ﬁxed 24 h posttransfection. Cells were permeabilized and
probed with primary antibodies mouse anti-V5 antibody (kindly provided by R. E. Randall, University of
St. Andrews), rabbit anti-FLAG antibody (F7425; Sigma), rabbit anti-TBK1/NAK antibody (3013; Cell
Signalling), rabbit anti-STAT1 p84/p91 antibody (sc-346; Santa Cruz Biotechnologies), and rabbit anti-
STAT2 antibody (sc-476; Santa Cruz Biotechnologies) and secondary antibodies anti-rabbit Alexa Fluor
488 and anti-mouse Alexa Fluor 568 (Thermo Fisher). The coverslips were mounted on slides using
Fluoromount-G with DAPI (4=,6-diamidino-2-phenylindole) (EBioscience). Fluorescently labeled proteins
were visualized using a Zeiss LSM-710 confocal microscope.
Expression plasmids and cloning. Fireﬂy luciferase reporter plasmids used to investigate IFN-
promoter or ISRE promoter activation, p(125)luc and p(9–27)4tkΔ(39)lucter, have been described
previously (95, 96). Control plasmid phRL-CMV coding for Renilla luciferase under the control of a
cytomegalovirus (CMV) promoter was purchased from Promega. Untagged or C-terminally V5-tagged
UUKV, HRTV, and SFTSV NSs sequences were cloned into the pCMV mammalian expression plasmid using
restriction-free cloning. FLAG-tagged RIG-I N, MAVS, TBK1, IKK, and IRF3-5D expression plasmids were
kindly provided by Mirko Schmolke (University of Geneva) and have been described elsewhere (97, 98).
Cloning of HRTV N and NSs protein into a bacterial expression plasmid. The coding region for
HRTV N protein was ampliﬁed and cloned into a modiﬁed pDEST14 vector (Invitrogen) using SacI and
XhoI restriction sites, generating plasmid p14 HRTV N. Plasmid pHaloHRTV NSs131-299 that expresses a
Halo fusion C-terminal domain (residues 131 to 299) of HRTV NSs protein was derived from
pH6HTNHisHaloTagT7-HRTV NSs, in which the full-length HRTV NSs was cloned into the modiﬁed
pH6HTNHisHaloTagT7 vector (Promega). Both p14HRTV N and pHaloHRTV NSs131-299 contain an
N-terminal 6-His tag for puriﬁcation of soluble HRTV N and NSs.
Expression and puriﬁcation of HRTV N and NSs protein for antibody production. N and NSs
proteins were expressed in Escherichia coli BL21 Rosetta2 (Merck) and C43(DE3) (a gift from Huanting Liu,
University of St. Andrews; originally from Lucigen Corporation) under conditions of IPTG (isopropyl--
D-thiogalactopyranoside) induction at 18 to 20°C for 18 h. Recombinant N and NSs proteins were puriﬁed
with nickel-nitrilotriacetic acid (Ni-NTA) resin. Recombinant NSs was further puriﬁed by gel ﬁltration
chromatography using a Superdex 200 10/300-Gl column. The puriﬁed N and NSs proteins were
conﬁrmed by mass spectrometry and used for generating rabbit polyclonal antibodies (Eurogentec).
Reporter assays. ISRE reporter assays were carried out as previously described (85). IFN- reporter
assays were performed by cotransfection of NSs proteins with expression plasmids encoding various
stimuli of the IFN- promoter (RIG-I N, MAVS, TBK1, IKK, and IRF3-5D) as described previously (85).
Brieﬂy, subconﬂuent HEK293T cells in a 24-well plate were transfected using 1.5 l TransIT LT-1 (Mirus
Bio LLC) and plasmid DNA and were lysed 24 h later. The total amount of plasmid DNA was kept constant
by addition of empty control plasmid. For ISRE reporter assays, transfected cells were stimulated with
500 U/ml of universal type I IFN (PBL Assay Science) and lysed 18 h post-IFN treatment. Fireﬂy and Renilla
luciferase activities in the reporter assays were measured using a dual-luciferase assay kit (Promega)
according to the manufacturer’s instructions.
The IFN response was also measured through biological IFN assays, as described previously (35, 64,
99). For infection experiments, IFN-competent A549 cells were infected with wt UUKV, HRTV, or SFTSV at
a low (0.1 FFU/cell) or high (3 FFU/cell) MOI. The cell culture medium was collected at the indicated time
points and inactivated by UV light exposure (8 W; 254 nm at a distance of 2 cm for 4 min with occasional
shaking). For transfection experiments, HEK293T cells induced by transfection of an expression plasmid
encoding the N terminus of RIG-I were cotransfected with the different NSs proteins, and the cell culture
medium was harvested 24 h p.t. Twofold dilutions of cell culture medium or UV-inactivated medium were
used to pretreat A549/BVDV-Npro cells for 24 h, followed by the addition of IFN-sensitive encephalo-
myocarditis virus (EMCV) (0.03 PFU/cell). Cell monolayers were stained with crystal violet 4 days later, and
the relative IFN units (RIU) were calculated as 2N, where N is the number of two-fold dilutions giving
A549/BVDV-Npro cells protection.
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Western blotting. Western blotting was performed as previously described (35) using the following
antibodies: anti-UUKV N monoclonal 8B11A3 (94), rabbit polyclonal UUKV NSs, HRTV and SFTSV poly-
clonal anti-N and anti-NSs (93), mouse anti-V5, mouse anti-FLAG M2 (F1804; Sigma), mouse anti--
tubulin (T5168; Sigma), mouse anti--actin (A5441; Sigma), anti-TBK1/NAK (3013; Cell Signalling), rabbit
anti-phospho-TBK1/NAK (Ser172) (5483S; Cell Signalling), rabbit anti-RIG-I (AT111; Enzo Life Sciences),
rabbit anti-IRF-3 (FL425; Sigma), rabbit anti-IRF-3 (phospho-S386) (76493; Abcam, Inc.), rabbit anti-STAT1
p84/p91 (sc-346; Santa Cruz Biotechnologies), rabbit anti-STAT2 (sc-476; Santa Cruz Biotechnologies),
rabbit antistat 1 Tyr701P (9167; Cell Signalling), rabbit antistat 1 Ser727P (9177; Cell Signalling), rabbit
antistat 2 Tyr690P (4441; Cell Signalling), and rabbit anti-STAT3 (sc-482; Santa Cruz Biotechnologies).
For detection of dimerized IRF-3, cells were lysed in a nonreducing lysis buffer (50 mM Tris HCl
[pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40) supplemented with protease and phosphatase
inhibitors, separated on a nonreducing gel, and transferred to a Hybond ECL nitrocellulose membrane
(GE Healthcare Life Sciences) prior to blocking in Tris-buffered saline (TBS)–0.1% Tween 20–3% bovine
serum albumin (BSA; Sigma) and probing with IRF-3 antibody. Upon incubation with horseradish
peroxidase (HRP)-coupled secondary antibody, proteins were detected using Clarity ECL blotting sub-
strate (Bio-Rad) and visualized with a Bio-Rad ChemiDoc imager.
Coimmunoprecipitation studies. Coimmunoprecipitation (co-IP) was carried out using either trans-
fected or infected cell monolayers. For transfections, subconﬂuent HEK293T cells were cotransfected with
expression plasmids encoding V5-tagged NSs proteins and plasmids encoding FLAG-tagged RIG-I N,
MAVS, TBK1, and IKK or IRF3-5D. For co-IP of NSs from virus-infected cells, HEK293T or A549 cells were
infected at an MOI of 20 or 5 with UUKV or HRTV, respectively. At the indicated time points, cells were
lysed in co-IP buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% NP-40,
supplemented with a cocktail of cOmplete protease inhibitors [Roche]) and incubated by rotation at 4°C
for 30 min. UUKV-infected cells were lysed in a different co-IP buffer (25 mM HEPES [pH 7.5], 150 mM
NaCl, 50 mM MgCl2, 1% Triton X-100, supplemented with a cocktail of cOmplete protease inhibitors
[Roche]). Cell lysates were clariﬁed by centrifugation at 12,000 rpm for 20 min at 4°C. At this stage, the
whole-cell lysate (WCL) fraction was taken.
For co-IP of FLAG-tagged proteins, anti-FLAG M2 magnetic beads (Sigma) were used for incubation
with clariﬁed cell lysates at 4°C for 4 h. For co-IP of UUKV NSs or HRTV NSs, clariﬁed cell lysates were
incubated overnight at 4°C with rabbit polyclonal anti-UUKV or anti-HRTV NSs antibody, respectively,
followed by the addition of protein A magnetic Dynabeads (Thermo Fisher). For co-IP of V5-tagged
proteins, clariﬁed cell lysates were incubated overnight at 4°C with mouse anti-V5 antibody, followed by
the addition of protein G magnetic Dynabeads (Thermo Fisher). All beads were used according to the
manufacturer’s instructions. Following incubation of the cell lysates with the beads for 1.5 h at 4°C, the
beads were washed ﬁve times with co-IP buffer and two times with PBS before elution of antibody
complexes was performed. Elution of proteins was carried out by the addition of reducing Laemmli
buffer and boiling at 95°C for 10 min. Eluates were analyzed by Western blotting, using a VeriBlot IP
secondary antibody (ab131366; Abcam, Inc.).
Quantitative RT-PCR. Total cellular RNA was extracted with RNAiso Plus (TaKaRa). Random hexamer
primers were used to synthesize cDNA using a Transcriptor First Strand cDNA synthesis kit (Roche), and
SYBR Premix Ex Taq II mix (TaKaRa) was used for real-time PCR (RT-PCR). Reactions were carried out in
triplicate on an ABI StepOnePlus system (Applied Biosystems). The relative levels of expression of mRNA
were calculated using threshold cycle (ΔΔCT) analysis, and the values were normalized to the relative
mRNA expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The following primers
were used: 5=-CCATTCTGATTTGCTGCCTTAT-3= and 5=-TTTCCTTGCTAACTGCTTTCAGTA-3= for CXCL10,
5=-CTGTGCGAGTGTACCGGATG-3= and 5=-ATCCCCACATGACTTCCTCTT-3= for IRF1, and 5=-GGAGCGAGAT
CCCTCCAAAAT-3= and 5=-GGCTGTTGTCATACTTCTCATGG-3= for GAPDH.
Statistical analysis. All data were analyzed using Prism 5 software (GraphPad) and are presented as
means  standard deviations (SD) or standard errors of the means (SEM). Statistical signiﬁcance for the
comparison of means between groups was determined by one-way or two-way analysis of variance
(ANOVA) followed by post hoc tests. P values of 0.05 were considered signiﬁcant (****, P  0.0001; ***,
P  0.001; **, P  0.01; *, P  0.05).
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FIG S1, TIF ﬁle, 10 MB.
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